Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Underweight on Dow, Raises Price Target to $39

Keybanc Maintains Underweight on Dow, Raises Price Target to $39

Keybanc analyst Aleksey Yefremov maintains Dow (NYSE:DOW) with a Underweight and raises the price target from $38 to $39.

byBenzinga Newsdesk

October 21, 2022

1 minute read

Keybanc analyst Aleksey Yefremov maintains Dow (NYSE:DOW) with a Underweight and raises the price target from $38 to $39.

4 Reasons Why This Ralph Lauren Analyst Is Bullish: ‘Lower Cotton, Freight Expenses’

By Priya Nigam

September 18, 11:45 AM

Shares of Ralph Lauren Corp (NYSE: RL) Monday continued their upward trajectory, after the spike on Friday last week.

Indaptus Therapeutics Announces Opening Of Next Cohort In Single Dose Ranging Study Of Decoy20

By Happy Mohamed

August 10, 8:48 AM

Cohort 1 patients exhibited a significant immune response consistent with the mechanism of action Safety Review Committee approved continuation to the next cohort

INDP

P/E Ratio Insights for AbbVie

By Benzinga Insights

May 17, 9:15 AM

In the current session, AbbVie Inc. (NYSE:ABBV) is trading at $143.27, after a 0.01% decrease. Over the past…

ABBV

What’s Going On With BioRestorative Therapies Stock?

By Erica Kollmann

June 17, 1:31 PM

BioRestorative Therapies shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements.

BRTX

Keybanc Maintains Underweight on Dow, Raises Price Target to $39

Related Posts

4 Reasons Why This Ralph Lauren Analyst Is Bullish: ‘Lower Cotton, Freight Expenses’

Indaptus Therapeutics Announces Opening Of Next Cohort In Single Dose Ranging Study Of Decoy20

P/E Ratio Insights for AbbVie

What’s Going On With BioRestorative Therapies Stock?